[
  {
    "id": "1130",
    "protocolNumber": "Test_Proto_01",
    "aidocId": "64c3dd08-f885-49f7-a325-e72d8f221029",
    "read": false,
    "details": "Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-Sensitive Prostate",
    "header": "Header",
    "timestamp": "2023-02-16T13:21:33.040000"
  },
  {
    "id": "1190",
    "protocolNumber": "Test_Proto_01",
    "aidocId": "64c3dd08-f885-49f7-a325-e72d8f221029",
    "read": true,
    "details": "Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-Sensitive Prostate",
    "header": "Header",
    "timestamp": "2021-06-16T13:21:33.040000"
  },

  {
    "id": "1649",
    "protocolNumber": "Bimal_patra_test_email_D361BC00001TC01",
    "header": "Header",
    "aidocId": "61232fdd-26d5-4e7c-8e86-624341910038",
    "read": true,
    "details": "Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-Sensitive Prostate",
    "timestamp": "2021-06-18T11:05:54.950000"
  },
  {
    "id": "1645",
    "protocolNumber": "Bimal_patra_test_email_D361BC00001TC01",
    "header": "Header",
    "aidocId": "953e212b-6d25-4614-ab80-0160a1abe660",
    "read": false,
    "details": "Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN deficiency.",
    "timestamp": "2021-06-18T09:38:59.113000"
  },
  {
    "id": "1807",
    "protocolNumber": "ARJ868TC23",
    "header": "Header",
    "aidocId": "ccca752d-840b-429b-b53a-42262cf212bb",
    "read": false,
    "details": "A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting ÃŸ2 Agonist in Patients with Uncontrolled Asthma",
    "timestamp": "2021-06-24T07:50:04.747000"
  },
  {
    "id": "1808",
    "protocolNumber": "BRPROTO3",
    "header": "Header",
    "aidocId": "ea39f739-a1a0-4994-a98b-08c298b662fd",
    "read": false,
    "details": "PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CORRECTION)",
    "timestamp": "2021-01-24T11:22:10.017000"
  },
  {
    "id": "1208",
    "protocolNumber": "BRPROTO3",
    "header": "Header",
    "aidocId": "ea39f739-a1a0-4994-a98b-08c298b662fd",
    "read": false,
    "details": "PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CORRECTION)",
    "timestamp": "2023-02-15T11:22:10.017000"
  }
]
